BioCentury | Oct 14, 2013
Finance

The VC spending gap

A new report from PricewaterhouseCoopers and the National Venture Capital Association shows the number of companies receiving first-time venture investments has fallen to lows not seen in nearly two decades. The data compiled by PwC...
BC Week In Review | Jul 30, 2012
Company News

Infinity management update

Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cambridge, Mass.   Business: Cancer, Inflammation   Hired: Lawrence Bloch as EVP, CFO and CBO, formerly CEO of NeurAxon Inc.  ...
BC Innovations | Jun 14, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Inducible nitric oxide synthase 2 (NOS2; iNOS); epidermal growth factor receptor variant III (EGFRvIII) In vitro and mouse studies suggest iNOS inhibitors could...
BC Innovations | Oct 6, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Neuronal nitric oxide synthase 1 (NOS1; nNOS) Rat and tissue culture studies identified 3,6-disubstituted indole derivative-based nNOS inhibitors that could help treat neuropathic pain....
BioCentury | Jun 20, 2011
Finance

Making the Milestone

Making the Milestone The venture arm of the Business Development Bank of Canada helped lead a C$13 million ($13.3 million) series A round last week in cardiovascular play Milestone Pharmaceuticals Inc. The financing is intended...
BC Week In Review | Nov 15, 2010
Clinical News

NXN-188: Phase II data

The double-blind, U.S. Phase II Study 204 trial in 174 patients with moderate to severe acute migraine headache without aura showed that a single dose of oral 600 mg NXN-188 missed the primary endpoint of...
BC Week In Review | Oct 4, 2010
Financial News

NeurAxon completes venture financing

NeurAxon Inc. , Waltham, Mass.   Business: Neurology   Date completed: 9/29/10   Type: Venture financing   Raised: $14 million   Investors: CTI Life Sciences Fund; Ontario Capital Growth Corp.; Delphi Ventures; OrbiMed Advisors; Venture West;...
BC Week In Review | Jan 4, 2010
Company News

NeurAxon board of directors update

NeurAxon Inc. , Waltham, Mass.   Business: Neurology   Appointed: Richard Meadows, managing director at CTI Life Sciences Fund L.P.  ...
BC Week In Review | Jan 4, 2010
Financial News

NeurAxon completes venture financing

NeurAxon Inc. , Waltham, Mass.   Business: Neurology   Date completed: 12/29/09   Type: Venture financing   Raised: $8.8 million   Investors: CTI Life Sciences Fund; Delphi Ventures; OrbiMed Advisors; Ventures West; H.I.G. Ventures; BDC Venture...
BioCentury | Sep 22, 2008
Finance

Shaking in their shorts

Shaking in their shortsA handful of heavily shorted small cap biotechs got a bounce last week after the U.S. Securities and Exchange Commission announced new actions intended to eliminate "naked" short selling - the abusive practice...
Items per page:
1 - 10 of 23
BioCentury | Oct 14, 2013
Finance

The VC spending gap

A new report from PricewaterhouseCoopers and the National Venture Capital Association shows the number of companies receiving first-time venture investments has fallen to lows not seen in nearly two decades. The data compiled by PwC...
BC Week In Review | Jul 30, 2012
Company News

Infinity management update

Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cambridge, Mass.   Business: Cancer, Inflammation   Hired: Lawrence Bloch as EVP, CFO and CBO, formerly CEO of NeurAxon Inc.  ...
BC Innovations | Jun 14, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Inducible nitric oxide synthase 2 (NOS2; iNOS); epidermal growth factor receptor variant III (EGFRvIII) In vitro and mouse studies suggest iNOS inhibitors could...
BC Innovations | Oct 6, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Neuronal nitric oxide synthase 1 (NOS1; nNOS) Rat and tissue culture studies identified 3,6-disubstituted indole derivative-based nNOS inhibitors that could help treat neuropathic pain....
BioCentury | Jun 20, 2011
Finance

Making the Milestone

Making the Milestone The venture arm of the Business Development Bank of Canada helped lead a C$13 million ($13.3 million) series A round last week in cardiovascular play Milestone Pharmaceuticals Inc. The financing is intended...
BC Week In Review | Nov 15, 2010
Clinical News

NXN-188: Phase II data

The double-blind, U.S. Phase II Study 204 trial in 174 patients with moderate to severe acute migraine headache without aura showed that a single dose of oral 600 mg NXN-188 missed the primary endpoint of...
BC Week In Review | Oct 4, 2010
Financial News

NeurAxon completes venture financing

NeurAxon Inc. , Waltham, Mass.   Business: Neurology   Date completed: 9/29/10   Type: Venture financing   Raised: $14 million   Investors: CTI Life Sciences Fund; Ontario Capital Growth Corp.; Delphi Ventures; OrbiMed Advisors; Venture West;...
BC Week In Review | Jan 4, 2010
Company News

NeurAxon board of directors update

NeurAxon Inc. , Waltham, Mass.   Business: Neurology   Appointed: Richard Meadows, managing director at CTI Life Sciences Fund L.P.  ...
BC Week In Review | Jan 4, 2010
Financial News

NeurAxon completes venture financing

NeurAxon Inc. , Waltham, Mass.   Business: Neurology   Date completed: 12/29/09   Type: Venture financing   Raised: $8.8 million   Investors: CTI Life Sciences Fund; Delphi Ventures; OrbiMed Advisors; Ventures West; H.I.G. Ventures; BDC Venture...
BioCentury | Sep 22, 2008
Finance

Shaking in their shorts

Shaking in their shortsA handful of heavily shorted small cap biotechs got a bounce last week after the U.S. Securities and Exchange Commission announced new actions intended to eliminate "naked" short selling - the abusive practice...
Items per page:
1 - 10 of 23